ACTRN12623000148673已完成1 期
Open-Label, Randomized, Fasted, Single Oral Dose, Crossover Trial to Assess the Relative Bioavailability of FP-045 and its Metabolite AD-835 After Single Doses of FP-045 2 X 75 mg Capsules (Test Drug) Compared to 150 mg Reconstituted FP-045 Drug Substance Liquid Formulation (Reference Drug) in Healthy Male Participants
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- Male
入选标准
- •Male participants between 18 to 55 years of age inclusive.
- •- Nonsmoker, ex-smoker, or light smoker who smokes <5 cigarettes/week and agrees to no smoking for 5 days before admission and has a negative urine cotinine test at admission (day -1).
- •- Participants who are overtly healthy based on assessment of medical history, physical examination, vital signs, ECGs, hematology, chemistry, and urinalysis assessments, serology, and other assessments.
- •- Body mass index between 18 and 32 kg/m2 inclusive.
- •- Males with female partners of childbearing potential agree to use a barrier contraceptive (ie, condom) and their female partners agree to use a highly effective method of contraception from Screening through 90 days after the last dose of the study drug. Males will agree to refrain from sperm donations during this time period. Males who are abstinent will not be required to use a contraceptive method unless they become sexually active.
排除标准
- •- History or presence of any clinically significant neurological, metabolic, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, chronic infections, psychiatric, or genitourinary abnormalities or diseases.
- •- History of malignant neoplastic disease, except for adequately treated non-melanomatous skin carcinoma.
- •- Mentally or legally incapacitated, had significant emotional problems at Screening or expected during the conduct of the study, or had a history of a clinically significant psychiatric disorder within 5 years before Screening.
- •- The participant has had a history of severe drug allergy or hypersensitivity or food allergy, including anaphylaxis.
- •- The participant has had surgery or trauma with significant blood loss within the last 3 months before the first dose of FP-045.
- •- The participant has donated more than 1 unit (500 mL) of blood within 4 weeks or plasma within one week before the first dose of FP-045.
- •- Clinically significant laboratory abnormalities including:
- •- Positive test for hepatitis C antibody, hepatitis B surface antigen, or human immunodeficiency virus antibody at Screening.
- •- Positive screen for drugs with a high potential for abuse.
- •- The participant exercises extensively (eg, marathon, triathlon, or similar high energy sports).
- •- A history or presence of any clinically significant endocrinologic abnormality or disease
- •- Use of prescription medications within 7 days (or within 5 half-lives, whichever is longer) of the first dose of FP-045.
研究者
相似试验
已完成
1 期
Comparative assessment in healthy male volunteers under fasting conditions of the absorption and pharmacokinetics of 1 generic formulation of (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid capsule against the innovator (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid capsuleIs used in the treatment of severe psoriasis in adult patients who have not responded to standard treatments.Skin - Dermatological conditionsACTRN12621000332820Zenith Technology Corporation Limited27
已完成
1 期
Comparative assessment in healthy male volunteers under fed conditions of the absorption and pharmacokinetics of 1 generic formulation of (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid capsule against the innovator (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid capsuleIs used in the treatment of severe psoriasis in adult patients who have not responded to standard treatments.Skin - Dermatological conditionsACTRN12621000331831Zenith Technology Corporation Limited33
尚未招募
4 期
To Evaluate Oral Bioavailability Efficacy of Co Enzyme Q10 100mg in Healthy Human Adult SubjectsCTRI/2022/10/046730Doctors Best Inc
尚未招募
不适用
Bioavailability study of Amaryl (glimepiride) Tablet 1 mg in healthy, adult, human subjects under fed conditioCTRI/2022/11/046993Sanofi Healthcare India Private Limited
尚未招募
1 期
Comparative Bioavailability Study of Ketorolac TromethamineSublingual Tablet 10 mg in healthy human subjectsCTRI/2024/05/067180Troikaa Pharmaceuticals Ltd